Santander International Selects Temenos and Syncordis to Launch its Digital Banking Platform in the Cloud and Become “future-ready”
6.4.2021 09:30:00 EEST | Business Wire | Press release
Syncordis, the global Temenos implementation partner and product experts, and Temenos (SIX: TEMN), the banking software company, announced that Santander International, part of the Banco Santander group, has selected Temenos SaaS, implemented by Syncordis, to power-up its core banking platform transformation.
Syncordis will help Santander International, which has branches in Jersey and the Isle of Man, to transform its banking, savings and mortgage products IT infrastructure from an on-premise solution to cloud-native Temenos SaaS. This will enable Santander International to benefit from the security, resilience and elastic scalability of the Microsoft Azure cloud.
Moving to the Temenos cloud-native and API-first digital banking platform with pre-configured banking and mortgages functionality will enable the bank to build and launch products faster and deliver enhanced digital experiences with streamlined customer journeys.
Syncordis has been selected as the system integrator and implementation partner to lead the core banking implementation and modernization project with a new digital banking eco-system. Adopting an agile implementation approach to complete the project delivery in the shortest timeframe, the bank’s customers will benefit from a smooth transition to Temenos’ next generation digital banking solution.
James Pountney, Chief Executive Officer Santander International, commented:
“In challenging times such as these, it is more vital than ever to be able to adapt to changing business and customer requirements simply, safely and swiftly. By working with Temenos and Syncordis we will be able to future-proof our digital banking platform which will enable us to provide our valued customers with outstanding service and a seamless customer experience.”
Hemal Jayasinghe, Chief Business Officer / Regional Director UK & NORDICS, Syncordis, said:
“We are excited to strategically partner with Santander International to modernize their core banking operations and drive their digitization journey. Innovation and the willingness to transform are key in today’s ever-changing world. With Temenos’ powerful cloud technology and Syncordis’ extensive implementation expertise, Santander International will be enabled to power their digital banking capabilities, provide an excellent and modern experience to their customers and future-proof their business.”
David Macdonald, President - Europe, Temenos, said:
“We’re excited to be working with Santander International to help redefine their customer experience. We see a growing momentum of banks both globally and in Europe choose Temenos as the most advanced cloud technology in the market to break free from legacy systems. Temenos SaaS delivers speed and agility while providing the security and resilience that a modern digital bank needs. We’re proud to be part of this evolution.”
Notes for Editors:
About Santander International:
Santander International is the trading name of the Jersey and Isle of Man branches of Santander Financial Services plc, a wholly owned subsidiary of Santander UK Group Holdings plc which is part of the Banco Santander group.
Santander International offers banking and savings accounts to Channel Island and Isle of Man residents, UK residents, UK expatriates, foreign expatriates and international customers. Santander International also offer mortgages on Jersey and Isle of Man properties and Corporate Banking solutions for Channel Island and Isle of Man domiciled companies. www.santanderinternational.co.uk
About Syncordis:
Syncordis, a Luxembourg based LTI Company, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software such as Temenos Infinity, Temenos Transact, Temenos Fund Administration, Temenos Infinity Wealth and Temenos DataSource. Syncordis is also the only Temenos global partner that is fully dedicated to Temenos services with capabilities to support all Temenos software suites. With 12 offices across the globe, 500+ experts and complementary services like SaaS and regulated production support services, Syncordis enables its international clients to master their digital transformation. This makes Syncordis one of the one-stop service partners for Temenos clients worldwide. For more information, please visit www.syncordisconsulting.com
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005020/en/
Contact information
Media Contact for Syncordis:
Clara Bechler
Marketing & Communication
T +49 40 369 835 12
E cbechler@syncordisconsulting.com
Media Contact for Santander International:
Susan Clark
Marketing & Communications
T +44 1534 828 011
susan.clark@santanderinternational.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom